Last updated on September 2020

A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)


Brief description of study

This is an open-label, multicenter, Phase 1/2 study to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Clinical Study Identifier: NCT03989414

Find a site near you

Start Over

Mayo Clinic

Rochester, MN United States
  Connect »

Sarah Cannon Cancer Center

Nashville, TN United States
  Connect »

Swedish Cancer Institute

Seattle, WA United States
  Connect »

Hotel Dieu CHU Nantes

Nantes Cedex 01, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.